A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer

類似資料

• Effects of HM30181, a P-glycoprotein inhibitor, on the pharmacokinetics and pharmacodynamics of loperamide in healthy volunteers
  著者:: Kim, Tae-Eun, 等
  出版事項: (2014)
• Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study
  著者:: Kim, Mi-Jung, 等
  出版事項: (2008)
• HM30181A, a potent P-glycoprotein inhibitor, potentiates the absorption and in vivo antitumor efficacy of paclitaxel in an orthotopic brain tumor model
  著者:: Zeng, Wu, 等
  出版事項: (2020)
• Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy
  著者:: Kim, Su-Jung, 等
  出版事項: (2010)
• Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy
  著者:: Lee, Kyung-Hun, 等
  出版事項: (2007)